Nrf2 prevents initiation but accelerates progression through the kras signaling pathway during lung carcinogenesis

Cancer Research

Volumn 73, Issue 13, 2013, Pages 4158-4168

  Satoh, Hironori ^a   Moriguchi, Takashi ^a   Takai, Jun ^a   Ebina, Masahito ^a   Yamamoto, Masayuki ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2E1; K RAS PROTEIN; TRANSCRIPTION FACTOR NRF2; URETHAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER SIZE; CANCER STAGING; CONTROLLED STUDY; FLOW CYTOMETRY; GENE MUTATION; LUNG CANCER; LUNG CARCINOGENESIS; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEFICIENCY; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

ADENOCARCINOMA; ANIMALS; BASE SEQUENCE; CELL TRANSFORMATION, NEOPLASTIC; CYTOCHROME P-450 CYP2E1; DNA MUTATIONAL ANALYSIS; LUNG; LUNG NEOPLASMS; MICE; MICE, INBRED ICR; MICE, KNOCKOUT; MICE, NUDE; MUTATION; MYELOID CELLS; NEOPLASM TRANSPLANTATION; NF-E2-RELATED FACTOR 2; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTO-ONCOGENE PROTEINS P21(RAS); SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; TRANSCRIPTOME; TUMOR BURDEN; TUMOR ESCAPE; URETHANE;

EID: 84880048347     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-4499     Document Type: Article

References (47)

1. Itoh K, Mimura J, Yamamoto M. Discovery of the negative regulator of Nrf2, Keap1: a historical overview. Antioxid Redox Signal 2010;13: 1665-78.
2. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 1997;236: 313-22.
3. Iida K, Itoh K, Kumagai Y, Oyasu R, Hattori K, Kawai K, et al. Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis. Cancer Res 2004;64: 6424-31.
4. Osburn WO, Karim B, Dolan PM, Liu G, Yamamoto M, Huso DL, et al. Increased colonic inflammatory injury and formation of aberrant crypt foci in Nrf2-deficient mice upon dextran sulfate treatment. Int J Cancer 2007;121: 1883-91.
5. Ramos-Gomez M, Kwak MK, Dolan PM, Itoh K, Yamamoto M, Talalay P, et al. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in Nrf2 transcription factordeficient mice. Proc Natl Acad Sci U S A 2001;98: 3410-5.
6. Xu C, Huang MT, Shen G, Yuan X, Lin W, Khor TO, et al. Inhibition of 7,12-dimethylbenz(a)anthracene-induced skin tumorigenesis in C57BL/6 mice by sulforaphane is mediated by nuclear factor E2- related factor 2. Cancer Res 2006;66: 8293-6.
7. Shibata T, Ohta T, Tong KI, Kokubu A, Odogawa R, Tsuta K, et al. Cancer related mutations in NRF2 impair its recognition by Keap1- Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci U S A 2008;105: 13568-73.
8. Wang R, An J, Ji F, Jiao H, Sun H, Zhou D. Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues. Biochem Biophys Res Commun 2008;373: 151-4.
9. Satoh H, Moriguchi T, Taguchi K, Takai J, Maher JM, Suzuki T, et al. Nrf2-deficiency creates a responsive microenvironment for metastasis to the lung. Carcinogenesis 2010;31: 1833-43.
10. Horio Y, Chen A, Rice P, Roth JA, Malkinson AM, Schrump DS. Ki-ras and p53 mutations are early and late events, respectively, in urethaneinduced pulmonary carcinogenesis in A/J mice. Mol Carcinog 1996; 17: 217-23.
11. Anderson N, Paul SH,Henry SM. Induction of pulmonary tumors in mice with ethyl carbamate (urethane). J Natl Cancer Inst 1943;4: 309-19.
12. Ghanayem BI, Hoffler U. Investigation of xenobiotics metabolism, genotoxicity, and carcinogenicity using Cyp2e1(+/-) mice. Curr Drug Metab 2007;8: 728-49.
13. Kemper RA, Myers SR, Hurst HE. Detoxification of vinyl carbamate epoxide by glutathione: evidence for participation of glutathione Stransferases in metabolism of ethyl carbamate. Toxicol Appl Pharmacol 1995;135: 110-8.
14. Hoffler U, Ghanayem BI. Increased bioaccumulation of urethane in CYP2E1-/- versus CYP2E1+/+ mice. Drug Metab Dispos 2005;33: 1144-50.
15. Gebel S, Diehl S, Pype J, Friedrichs B, Weiler H, Schuller J, et al. The transcriptome of Nrf2-/- mice provides evidence for impaired cell cycle progression in the development of cigarette smoke-induced emphysematous changes. Toxicol Sci 2010;115: 238-52.
16. Ihara S, Kida H, Arase H, Tripathi LP, Chen YA, Kimura T, et al. Inhibitory roles of signal transducer and activator of transcription 3 in antitumor immunity during carcinogen-induced lung tumorigenesis. Cancer Res 2012;72: 2990-9.
17. Stathopoulos GT, Sherrill TP, Cheng DS, Scoggins RM, Han W, Polosukhin VV, et al. Epithelial NF-kappaB activation promotes urethane-induced lung carcinogenesis. Proc Natl Acad Sci U S A 2007; 104: 18514-9.
18. Forkert PG. Mechanisms of lung tumorigenesis by ethyl carbamate and vinyl carbamate. Drug Metab Rev 2010;42: 355-78.
19. Cho HY, Kleeberger SR. Nrf2 protects against airway disorders. Toxicol Appl Pharmacol 2010;244: 43-56.
20. Mitsuishi Y, Taguchi K, Kawatani Y, Shibata T, Nukiwa T, Aburatani H, et al. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell 2012;22: 66-79.
21. Pacheco-Pinedo EC, Durham AC, Stewart KM, Goss AM, Lu MM, Demayo FJ, et al. Wnt/beta-catenin signaling accelerates mouse lung tumorigenesis by imposing an embryonic distal progenitor phenotype on lung epithelium. J Clin Invest 2011;121: 1935-45.
22. Cardoso CC, Bornstein SR, Hornsby PJ. New methods for investigating experimental human adrenal tumorigenesis. Mol Cell Endocrinol 2009;300: 175-9.
23. Brigelius-Flohe R, Kipp A. Glutathione peroxidases in different stages of carcinogenesis. Biochim Biophys Acta 2009;1790: 1555-68.
24. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000;92: 1295-302.
25. Borczuk AC, Gorenstein L, Walter KL, Assaad AA, Wang L, Powell CA. Non-small-cell lung cancer molecular signatures recapitulate lung developmental pathways. Am J Pathol 2003;163: 1949-60.
26. Jiang SS, Fang WT, Hou YH, Huang SF, Yen BL, Chang JL, et al. Upregulation of SOX9 in lung adenocarcinoma and its involvement in the regulation of cell growth and tumorigenicity. Clin Cancer Res 2010;16: 4363-73.
27. Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007;450: 893-8.
28. Wan H, Dingle S, Xu Y, Besnard V, Kaestner KH, Ang SL, et al. Compensatory roles of Foxa1 and Foxa2 during lung morphogenesis. J Biol Chem 2005;280: 13809-16.
29. Meuwissen R, Berns A. Mouse models for human lung cancer. Genes Dev 2005;19: 643-64.
30. Pestell RG, Albanese C, Reutens AT, Segall JE, Lee RJ, Arnold A. The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation. Endocr Rev 1999;20: 501-34.
31. Lee GH. The Kras2 oncogene and mouse lung carcinogenesis. Med Mol Morphol 2008;41: 199-203.
32. DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 2011;475: 106-9.
33. Dragani TA, Manenti G, Pierotti MA. Genetics of murine lung tumors. Adv Cancer Res 1995;67: 83-112.
34. Chambers AF, Wilson SM, Kerkvliet N, O'Malley FP, Harris JF, Casson AG. Osteopontin expression in lung cancer. Lung Cancer 1996;15: 311-23.
35. Hsieh YH, Juliana MM, Hicks PH, Feng G, Elmets C, Liaw L, et al. Papilloma development is delayed in osteopontin-null mice: implicating an antiapoptosis role for osteopontin. Cancer Res 2006;66: 7119-27.
36. Okayama H, Kohno T, Ishii Y, Shimada Y, Shiraishi K, Iwakawa R, et al. Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res 2012;72: 100-11.
37. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010;10: 9-22.
38. Brauer PM, Tyner AL. Building a better understanding of the intracellular tyrosine kinase PTK6 - BRK by BRK. Biochim Biophys Acta 2010;1806: 66-73.
39. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9: 162-74.
40. Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, et al. Altered recognition of antigen is a mechanism of CD8+T cell tolerance in cancer. Nat Med 2007;13: 828-35.
41. Liu CY, Wang YM, Wang CL, Feng PH, Ko HW, Liu YH, et al. Population alterations of L-arginase-and inducible nitric oxide synthaseexpressed CD11b+/CD14/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol 2010;136: 35-45.
42. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007;7: 295-308.
43. Khor TO, Huang MT, Prawan A, Liu Y, Hao X, Yu S, et al. Increased susceptibility of Nrf2 knockout mice to colitis-associated colorectal cancer. Cancer Prev Res (Phila Pa) 2008;1: 187-91.
44. Hinoi E, Takarada T, Fujimori S, WangL, Iemata M, Uno K, et al. Nuclear factor E2 p45-related factor 2 negatively regulates chondrogenesis. Bone 2007;40: 337-44.
45. Kensler TW, Wakabayashi N. Nrf2: friend or foe for chemoprevention? Carcinogenesis 2010;31: 90-9.
46. Zhang Y, Munday R. Dithiolethiones for cancer chemoprevention: where do we stand? Mol Cancer Ther 2008;7: 3470-9.
47. Pergola PE, Raskin P, Toto RD, Meyer CJ, Huff JW, Grossman EB, et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 2011;365: 327-36.